Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
Biomarker
Metastatic non‒small-cell lung cancer
Pembrolizumab
Single-gene genetic alterations
Tissue tumor mutational burden
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
27
10
2022
accepted:
27
10
2022
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
We evaluated tissue tumor mutational burden (tTMB) and mutations in This retrospective exploratory analysis evaluated prevalence of high tTMB and Among patients with evaluable data from whole-exome sequencing for evaluation of tTMB (KEYNOTE-189, These findings support pembrolizumab-combination as first-line treatment in patients with metastatic NSCLC and do not suggest the utility of tTMB,
Identifiants
pubmed: 36793385
doi: 10.1016/j.jtocrr.2022.100431
pii: S2666-3643(22)00155-2
pmc: PMC9923193
doi:
Banques de données
ClinicalTrials.gov
['NCT02578680', 'NCT02775435']
Types de publication
Journal Article
Langues
eng
Pagination
100431Informations de copyright
© 2022 The Authors.
Références
Lung Cancer. 2019 Apr;130:50-58
pubmed: 30885352
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Ann Oncol. 2017 Jan 1;28(1):75-82
pubmed: 27687306
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Genes Chromosomes Cancer. 2019 Aug;58(8):578-588
pubmed: 30664300
ESMO Open. 2020 Apr;5(2):
pubmed: 32312757
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35101941
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Thorac Dis. 2019 Jan;11(Suppl 1):S71-S80
pubmed: 30775030
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
ESMO Open. 2021 Jun;6(3):100124
pubmed: 33940346
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Lung Cancer. 2019 Jul;133:144-150
pubmed: 31200821
Clin Cancer Res. 2020 May 15;26(10):2354-2361
pubmed: 32102950
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217756
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
JAMA Oncol. 2020 May 1;6(5):661-674
pubmed: 32271377
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Cell Metab. 2018 Apr 3;27(4):935-943.e4
pubmed: 29526543
JCO Precis Oncol. 2017;2017:
pubmed: 29951597